Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism

Image: Promentis Pharmaceuticals announces commencement of phase 2 studies for SXC-2023 targeting novel Glutamatergic mechanism. Photo: courtesy of ponsulak/Freedigitalphotos.net.